Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Baer

Showing results (451-460 of 628) with videos related to

Pageof 63
Sort By:
Bone Marrow Transplantation|July 3, 2003
Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftmentT Hahn, U Bunworasate, M C George, et al.
Acta Haematologica|January 30, 2019
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and PonatinibFiras El Chaer, Noa G Holtzman, Edward A Sausville, et al.
Blood Advances|July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndromeJorge E Cortes, Jay Yang, Gail J Roboz, et al.
Biomolecules|January 8, 2025
Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive SamplingWilliam Middlezong, Victoria Stinnett, Michael Phan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administeredJ C Byrd, R K Dodge, A Carroll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIvana Gojo, Ming Tan, Hong-Bin Fang, et al.
British Journal of Haematology|December 6, 2019
Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemiaNoa G Holtzman, Firas El Chaer, Maria R Baer, et al.
Annals of Hematology|October 10, 2025
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinibAjibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Biology|June 24, 2022
Impact of <i>FLT3</i>-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort StudyElizabeth M Corley, Moaath K Mustafa Ali, Hanan Alharthy, et al.
Mycopathologia|March 17, 2005
Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristicsAasma Shaukat, Faris Bakri, Paul Young, et al.
Pageof 63

Showing results (451-460 of 628) with videos related to

Sort By:
Pageof 63
Bone Marrow Transplantation|July 3, 2003
Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftmentT Hahn, U Bunworasate, M C George, et al.
Acta Haematologica|January 30, 2019
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and PonatinibFiras El Chaer, Noa G Holtzman, Edward A Sausville, et al.
Blood Advances|July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndromeJorge E Cortes, Jay Yang, Gail J Roboz, et al.
Biomolecules|January 8, 2025
Rapid Detection of <i>PML::RARA</i> Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive SamplingWilliam Middlezong, Victoria Stinnett, Michael Phan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administeredJ C Byrd, R K Dodge, A Carroll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIvana Gojo, Ming Tan, Hong-Bin Fang, et al.
British Journal of Haematology|December 6, 2019
Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemiaNoa G Holtzman, Firas El Chaer, Maria R Baer, et al.
Annals of Hematology|October 10, 2025
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinibAjibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Biology|June 24, 2022
Impact of <i>FLT3</i>-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort StudyElizabeth M Corley, Moaath K Mustafa Ali, Hanan Alharthy, et al.
Mycopathologia|March 17, 2005
Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristicsAasma Shaukat, Faris Bakri, Paul Young, et al.
Pageof 63